INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,181,500 | +410.0% | 1,193,732 | +519.9% | 0.73% | +402.8% |
| Q2 2023 | $12,192,646 | -41.2% | 192,556 | -50.9% | 0.14% | -47.8% |
| Q4 2022 | $20,746,228 | +54.6% | 392,030 | +36.0% | 0.28% | +48.7% |
| Q3 2022 | $13,416,000 | +84.6% | 288,326 | +126.4% | 0.19% | +67.0% |
| Q2 2022 | $7,269,000 | -27.2% | 127,342 | -56.7% | 0.11% | -49.3% |
| Q1 2021 | $9,985,000 | -3.3% | 294,285 | -9.4% | 0.22% | -19.3% |
| Q4 2020 | $10,328,000 | – | 324,767 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |